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Inflammatory processes are prominent in various types of human and experimental pulmonary hypertension (PH) and
are increasingly recognized as major pathogenic components of pulmonary vascular remodeling. Macrophages, T and
B lymphocytes, and dendritic cells are present in the vascular lesions of PH, whether in idiopathic pulmonary arterial
hypertension (PAH) or PAH related to more classical forms of inflammatory syndromes such as connective tissue dis-
eases, human immunodeficiency virus (HIV), or other viral etiologies. Similarly, the presence of circulating chemo-
kines and cytokines, viral protein components (e.g., HIV-1 Nef), and increased expression of growth (such as vascular
endothelial growth factor and platelet-derived growth factor) and transcriptional (e.g., nuclear factor of activated T
cells or NFAT) factors in these patients are thought to contribute directly to further recruitment of inflammatory cells
and proliferation of smooth muscle and endothelial cells. Other processes, such as mitochondrial and ion channel
dysregulation, seem to convey a state of cellular resistance to apoptosis; this has recently emerged as a necessary
event in the pathogenesis of pulmonary vascular remodeling. Thus, the recognition of complex inflammatory distur-
bances in the vascular remodeling process offers potential specific targets for therapy and has recently led to clinical
trials investigating, for example, the use of tyrosine kinase inhibitors. This paper provides an overview of specific in-
flammatory pathways involving cells, chemokines and cytokines, cellular dysfunctions, growth factors, and viral pro-
teins, highlighting their potential role in pulmonary vascular remodeling and the possibility of future targeted
therapy. (J Am Coll Cardiol 2009;54:S10–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.006r
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Bulmonary arterial hypertension (PAH) constitutes a
eterogeneous group of clinical entities sharing similar
athologies that have been subcategorized as idiopathic
ulmonary arterial hypertension (IPAH), familial PAH,
ulmonary hypertension (PH) associated with other dis-
ases such as connective tissue diseases, (e.g., systemic
clerosis [SSc]), portopulmonary hypertension, and PH
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nflammation plays a significant role in various types of
uman PH, such as IPAH and PAH associated with
onnective tissue diseases and HIV infection and in
xperimental animal models (e.g., monocrotaline
MCT]-induced PH). A subset of PAH patients have
irculating autoantibodies, including antinuclear anti-
odies (2), and elevated circulating levels of the proin-
ammatory cytokines interleukin (IL)-1 and IL-6 (3).
lthough there are serologic and pathologic features
uggestive of inflammation in both IPAH and PAH
elated to SSc (PAH-SSc) or other connective tissue
iseases, it is likely that inflammatory pathways and
utoimmunity are more pronounced in PAH-SSc. This
ight explain survival discrepancies and differential re-
ponse to therapy between the 2 syndromes (4). As such,
AH-SSc might be considered the prototypic syndrome
n which to study inflammatory processes potentially
perative in the pathogenesis of PAH.
A role for inflammation in PAH is based on the finding
f inflammatory cells, including macrophages and T and B
ymphocytes, and dendritic cells around the plexiform le-
ions of PAH (5). Levels of macrophage inflammatory
rotein-1, IL-1 and -6 (3,6), and P-selectin (7) are
ncreased in severe IPAH. Involvement of leukocytes, mac-
ophages, and lymphocytes in the complex vascular lesions
f IPAH was initially described by Tuder et al. (8) and
onfirmed in more recent studies by Dorfmüller et al. (9).
ytokine- and chemokine-dependent mechanisms leading
o inflammatory cell recruitment in human PAH are also
rominent in PAH.
ytokines and chemokines in PAH. Balabanian et al.
10) demonstrated that fractalkine (CX3CL1), a unique
hemokine that promotes the chemokine (C-X3-C motif)
eceptor 1 (CX3CR1)-expressing leukocyte recruitment, is
pregulated in circulating CD4 and CD8 T lymphocytes
rom PAH patients as compared with control subjects.
hese patients also have elevated soluble CX3CL1 plasma
oncentrations; their lung tissue samples demonstrate in-
reased CX3CL1 messenger ribonucleic acid (mRNA) ex-
ression as compared with control subjects, and pulmonary
rtery (PA) endothelial cells (ECs) from these lungs express
X3CL1 protein.
Regulated upon Activation, Normal T cell expressed and
ecreted (RANTES, also known as CCL5) is an important
hemoattractant for monocytes and T-cells. CCL5 plays a
ey role in several vascular inflammatory processes such as
lomerulonephritis, Kawasaki disease, and Takayasu’s ar-
eritis. CCL5 might also play an indirect role in PAH
hrough the induction of endothelin (ET)-converting
nzyme-1 and ET-1, a potent endothelium-derived factor
ith strong vasoconstrictive and mitogenic action. Indeed,
CL5 mRNA expression is increased in lung samples from
AH patients as compared with control subjects and prob- mbly originates from ECs, as
emonstrated by in situ hybrid-
zation and immunohistochemis-
ry (11). The exact relevance of
hese findings to the pathophys-
ology of PAH requires further
nvestigation.
Two recent studies further sug-
est that chemokines produced
rom small PAs of PAH patients
ight contribute to inflammatory
ell recruitment and PA smooth
uscle cell (SMC) proliferation.
erros et al. (12) demonstrated
hat CX3CL1 is expressed by in-
ammatory cells surrounding PA
esions and that SMCs from these
essels have increased CX3CR1
xpression. In addition, cultured
at PA-SMCs express CX3CR1,
nd CX3CL1 induces prolifera-
ion but not migration of these
ells. Therefore, fractalkine might
ct as a growth factor for PA-
MCs. The hypothesis that che-
okines might play a role in PA
emodeling was further studied by
anchez et al. (13). Compared
ith control subjects, IPAH pa-
ients have elevated levels of
CL2, also known as monocyte
hemotactic protein (MCP)-1, in
lasma and lung tissue. In addition
levated CCL2 release from pul-
onary ECs or PA-SMCs was
emonstrated. Monocyte migra-
ion was markedly increased in the
resence of pulmonary ECs (par-
icularly from patients with
PAH) and significantly reduced
y CCL2-blocking antibodies. Fi-
ally, compared with control sub-
ects, PA-SMCs from patients ex-
ibited stronger migratory and
roliferative responses to CCL2,
n keeping with the finding that
CR2 was markedly increased in
A-SMCs in these patients (13).
rowth factors and inflamma-
ion in PAH. Several growth
actors, including platelet-derived
rowth factor (PDGF) (14,15),
pidermal growth factor (EGF)
16), and vascular endothelial growth factor (VEGF) (17),
ave been implicated in the abnormal proliferation and
Abbreviations
and Acronyms
AECA  anti-endothelial
cell antibody
bcl  B-cell lymphoma
COPD  chronic obstructive
pulmonary disease
EC  endothelial cell
EGF  epidermal growth
factor
ET  endothelin
HCV  hepatitis C virus
HHV  human herpes virus
HIV  human
immunodeficiency virus
5-HT  serotonin
5-HTT  serotonin
transporter
IL  interleukin
IPAH  idiopathic
pulmonary arterial
hypertension
Kv  voltage-dependent
potassium channel
MCT  monocrotaline
mRNA  messenger
ribonucleic acid
NFAT  nuclear factor of
activated T cells
PA  pulmonary artery
PAH  pulmonary arterial
hypertension
PCR  polymerase chain
reaction
PDGF  platelet-derived
growth factor
PDGFR  platelet-derived
growth factor receptor
PH  pulmonary
hypertension
RV  right ventricular
SIV  simian
immunodeficiency virus
SMC  smooth muscle cell
SSc  systemic sclerosis
TGF  transforming growth
factor
TN  tenascin
TNF  tumor necrosis factor
VEGF  vascular
endothelial growth factorigration of PA vascular cells. They act as potent mitogens
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Pulmonary Vascular Remodeling June 30, 2009:S10–9nd chemoattractants for SMCs, fibroblasts, and ECs and
ause resistance to apoptosis.
EGF. Cool et al. (18) demonstrated intense expression of
he VEGF receptor KDR, coupled with a reduced expres-
ion of p27/kip1, a cell cycle inhibitory protein, in the ECs
f plexiform lesions. Other markers of angiogenesis, such as
EGF and hypoxia inducible factor-1 subunits  and , are
ighly expressed in ECs of plexiform lesions in severe PAH
19). In addition, expression of C-Src kinase (19), a protein
hat mediates VEGF-induced production of prostacyclin
nd nitric oxide in ECs, is decreased in PAH. Taken
ogether, these findings suggest a central role in PAH for
EGF, a mediator of angiogenesis but also a factor involved
n permeability and inflammatory processes in the vascular
ndothelium.
DGF. Platelet-derived growth factor is synthesized by many
ifferent cell types including SMCs, ECs, and macrophages.
DGF induces the proliferation and migration of SMCs
nd fibroblasts and has been proposed as a key mediator in
he progression of several fibroproliferative disorders such as
therosclerosis, lung fibrosis, and PH (14). As a result, novel
herapeutic agents, such as tyrosine kinase inhibitors, have
een tested in experimental models of PH (15) and more
ecently in clinical trials. The rationale for use of these
gents is discussed in more detail in later sections. The
athogenic role of PDGF was demonstrated by increased
xpression of PDGF and platelet-derived growth factor
eceptors (PDGFRs) by reverse transcription-polymerase
hain reaction (PCR) performed on laser-captured micro-
issected PAs from native lungs of patients with severe
PAH who underwent lung transplantation (20). The
DGF-A, PDGF-B, PDGF-R , and PDGF-R  mRNA
xpression is increased in small PAs from patients with
evere IPAH as compared with control subjects. In small
As, PDGF-B is mainly expressed in ECs, SMCs, and in
ome perivascular inflammatory cells, and PDGFR- is
ainly expressed in SMCs. The PDGF-BB–induced pro-
iferation and migration of PA-SMCs is inhibited by
matinib (20). Taken together, these data support the
oncept that PDGF is overproduced and promotes PA
emodeling in PAH.
GF. The EGF-dependent proliferation and migration of
MCs is dependent on the extracellular matrix component
enascin C (TN-C). In addition, EGF colocalizes with
N-C in PAH lesions (21), suggesting a direct role in
isease progression. It is noteworthy that the EGF receptor
nhibitor PKI166 reverses established MCT-induced PH in
ats (16).
EROTONIN AND SEROTONIN TRANSPORTER. In addition to
ts vasoactive effects, serotonin (5-HT) exerts mitogenic and
o-mitogenic effects on PA-SMCs. In contrast to the
onstricting action of 5-HT on SMCs, which is mainly
ediated by 5-HT receptors (5-HT 1B/D, 2A, and 2B)22), the mitogenic and co-mitogenic effects of 5-HT tequire internalization of indoleamine by serotonin trans-
orter (5-HTT) (23). Accordingly, drugs that competitively
nhibit 5-HTT also block the mitogenic effects of 5-HT on
MCs (24).
Serotonin transporter is abundantly expressed in the lung,
here it is predominantly located in PA-SMCs (24). Direct
vidence that 5-HTT plays a key role in PA remodeling is
upported by studies showing that mice with targeted
-HTT gene disruption develop less severe hypoxic PH
han wild-type control subjects (25) and that selective
-HTT inhibitors attenuate hypoxia- and MCT-induced
H (26). Conversely, increased 5-HTT expression is asso-
iated with increased severity of hypoxic PH (27). Trans-
enic mice with selective overexpression of 5-HTT in
MCs spontaneously develop PH (28). Pulmonary hyper-
ension seems to develop in these mice without any alter-
tions in 5-HT bioavailability and as a sole consequence of
he increased expression of 5-HTT in SMCs. Taken to-
ether, these observations suggest a close correlation be-
ween 5-HTT expression and/or activity and the extent of
A remodeling during experimental PH.
Serotonin transporter expression is increased in platelets
nd in the media of thickened PAs in IPAH (24). The
A-SMCs from patients with IPAH grow faster than
A-SMCs from control subjects when stimulated by 5-HT
r serum, as a consequence of increased 5-HTT expression
24). In the presence of 5-HTT inhibitors, the growth-
timulating effects of serum and 5-HT are markedly re-
uced, and the difference between growth of PA-SMCs
rom patients and control subjects was abolished. Taken
ogether, 5-HTT overexpression and/or activity in PA-
MCs from IPAH patients seem responsible for the in-
reased mitogenic response to 5-HT. The 5-HT is synthe-
ized by ECs in the normal lung as a result of tryptophan
ydroxylase-1 enzyme activity and seems to be the main
rowth factor produced by ECs, acting on PA-SMCs in a
aracrine fashion. In conclusion, PA-SMC hyperplasia in
PAH seems to result from both dysregulation of 5-HT
roduction by ECs due to overexpression of tryptophan
ydroxylase-1 and from an increased PA-SMC response to
-HT due to overexpression of the 5-HTT (29).
URVIVIN. Survivin (16.5 kDa) is the smallest member of the
ammalian inhibitor of the apoptosis family. Several ma-
ignant processes have been linked to dysregulation of
urvivin expression. The normal absence of survivin from
ealthy tissues suggests it is a potential target for therapy.
urvivin is overexpressed in PAs from PAH patients and in
ats with MCT-induced PAH, compared with control
ubjects (30). Wild-type survivin delivered via an inhaled
denovirus to normal rats causes PH. Conversely, gene
herapy with an adenovirus carrying a phosphorylation-
eficient survivin mutant with dominant-negative proper-
ies (T34A survivin) reverses established MCT-PAH and
rolongs survival (30). Administration of the survivin mu-
ant reduces pulmonary vascular resistance, right ventricular
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June 30, 2009:S10–9 Pulmonary Vascular RemodelingRV) hypertrophy, and PA medial hypertrophy. Both in
itro and in vivo, inhibition of endogenous survivin induces
A-SMC apoptosis, depolarizes mitochondria, causes efflux
f cytochrome c in the cytoplasm, translocates apoptosis-
nducing factor into the nucleus, and increases voltage-
ependent potassium channel (Kv) current, whereas the
pposite effects are observed with gene transfer of wild-type
urvivin. Survivin also induces the production of the PDGF
eceptor in human vascular SMCs (31). Therefore, the pro-
osed causative role of survivin in PAH and the lack of its
xpression in normal PA wall and systemic vasculature make
his gene attractive for future targeted therapy in PAH.
ranscriptional factors: the nuclear factor of activated
cells in inflammation and vascular remodeling. The
uclear factor of activated T cells (NFAT), originally
escribed in T cells, is a master activator of T cells,
ncreasing the transcription of multiple inflammatory me-
iators, including many interleukins and tumor necrosis
actor (TNF), and activating T and B cells (32). Increased
Ca2]i activates calcineurin, which dephosphorylates cyto-
lasmic NFAT, allowing its entry to the nucleus, where it
orms complexes with other important transcription factors
e.g., GATA or activator protein-1) and regulates gene
ranscription (32).
Several recent observations suggest that NFAT might be
nvolved in PAH. The NFAT activation causes downregu-
ation of Kv1.5 (33), which plays a preponderant role in
ulmonary vasoconstriction. Second, ET (upregulated in
AH) activates NFAT, which in turn increases B-cell
ymphoma (bcl)-2 expression, contributing to the prosur-
ival and antiapoptotic effects of ET in the heart (34).
hird, NFAT directly or indirectly regulates the transcrip-
ion of several genes that regulate mitochondrial function
e.g., pyruvate decarboxylase and the electron transport
hain enzyme cytochrome C oxidase) (35).
The NFAT is upregulated and activated (i.e., translo-
ated in the nucleus) in circulating inflammatory cells in
atients with PAH, including IPAH and PAH-SSc. The
D3-positive cells with activated NFAT are also seen in
emodeled PAs. Intriguingly, NFAT is also activated in the
A-SMCs of remodeled arteries. The PA-SMCs isolated
rom PAH patients maintain in culture a unique phenotype
downregulated Kv1.5, upregulated bcl-2, hyperpolarized
itochondria), which is associated with activated NFAT
nd resistance to apoptosis. The NFAT is not activated in
ormal lungs and PA-SMCs. The unique phenotype of
AH PA-SMCs is normalized by selective inhibition of
FAT.
Inhibition of NFATc2 (predominant NFAT isotype in
AH) by VIVIT (a competitive peptide that inhibits the
ocking of NFAT to calcineurin) or cyclosporine (inhibitor
f calcineurin), restores Kv1.5 expression and current and
ecreases [Ca2]i, [K
]i, bcl-2, and mitochondrial mem-
rane potential (m), leading to increased apoptosis
n vitro (36). In vivo, cyclosporine treatment decreases
stablished MCT-induced PAH in the rat (36). Intrigu- tngly, PA-SMCs exposed to chronic hypoxia display NFAT
ctivation, hyperpolarized mitochondria, and downregu-
ated Kv1.5, similar to the SMC phenotype of PAH.
nhibition with VIVIT or cyclosporine reverses this pheno-
ype, normalizing the mitochondrial membrane potential
nd level/function of Kv1.5 in these cells. There has been
ecent interest in developing specific NFAT inhibitors for
he treatment of cardiac hypertrophy and failure (37).
herefore, in PAH, NFAT inhibitors might contribute to
eversing RV hypertrophy and pulmonary vascular remod-
ling through their effects on cardiomyocytes, PA-SMCs,
nd inflammatory cells.
iral and Other Infectious Etiologies in PAH
ypothetically, PH is caused by latent viral infections,
ecause associations between Epstein Barr virus infection
nd Hodgkin’s disease and parvovirus and cytomegalovi-
us infection and SSc have been described (38); both
iseases have also been associated with PH. Infectious
rganisms can affect the lung circulation directly, by
bliterating lung vessels, or indirectly, by causing and
aintaining inflammation.
However, there is little evidence for a “direct” role for
nfectious agents in the pathogenesis of severe PH. Even in
chistosomiasis-associated PH, it is unclear to what extent
iver disease and therefore portopulmonary hypertension
ominate the pathobiology of PH. Schistosoma eggs mod-
late regulatory T-cell activity and express a novel member
f the transforming-growth factor (TGF)- superfamily,
chistosoma mansoni inhibin/activin (SmInAct) (39). Re-
ently a mouse model of pneumocystis-induced PH associ-
ted with muscularized PAs has been reported (40), and
aley et al. (41) reported a mouse model of highly muscu-
arized PAs after a regimen of aspergillus antigen (ag)
mmunization.
ole of human herpes virus-8, HIV, and SHIV-Nef in
ulmonary vascular remodeling. Pulmonary arterial hy-
ertension has a prevalence of 0.0002% in the general
opulation, but in HIV-infected individuals the prevalence
s 0.46% in France (42). The HIV-related PAH (HRPAH)
s independent of CD4 T cell counts (43) and antiviral
rug treatment. The clinical features of HRPAH are similar
o PAH of other etiologies. Although highly active antiret-
oviral therapy might have decreased the incidence of
RPAH and might partially reverse PH in a small number
f HIV-1–infected individuals only when combined with
H-specific treatment such as bosentan (44), this disease
emains a significant clinical complication in the HIV-1–
nfected population. Other studies showed no correlation
etween viral load and right heart changes (45).
Most of the pathways involved in virus pathogenesis
onverge on either prosurvival or proangiogenic signals, the
ame signals associated with PH. In the lung, HIV-1 infects
rimarily macrophages, providing a potential reservoir for the
ransmission of the virus to circulating T-cells, and is a source
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Pulmonary Vascular Remodeling June 30, 2009:S10–9or localized viral proteins such as Nef, Tat, and gp120, which
ight have direct or indirect effects. Chronic exposure to these
iral products as well as deficiency in regulatory T cells and
ltered production of chemokines/cytokines might contribute
o pulmonary vascular dysfunction.
Macaques infected with chimeric SHIV-nef virions (sim-
an immunodeficiency virus [SIV]mac239 nef virus contain-
ng a cloned HIV-1 nef gene) demonstrate lung vascular
hanges characteristic of PAH, whereas macaques infected
ith parental SIV strains containing the native SIV nef
llele show no vascular remodeling (46). The Nef was also
emonstrated by immunohistochemistry in lungs of HIV-
nfected patients with PH (47). Thus, HIV-1 Nef protein,
erhaps in conjunction with host genetic factors and/or
ersistent immune dysregulation, contributes to the devel-
pment of pulmonary vascular remodeling. Foci of mono-
uclear cells and ectopic lymphoid tissues adjacent to the
esions might be sources of this viral protein.
The HIV-1 Nef is 1 of the accessory proteins made early
n HIV infection and whose major effects are downregulat-
ng CD4 (48) and blocking major histocompatibility
ntigen-I trafficking to the membrane (49), allowing the
nfected cells to evade immune surveillance (50). In human
onocyte-derived macrophages, Nef activates the STAT1
athway and the secretion of MIP-1, IL-1-, IL-6, and
NF (51).
uman gamma herpes virus 8. Human gamma herpes
irus 8 (HHV8), also known as Kaposi’s sarcoma-associated
erpes virus, has been associated with angioproliferation
52). The HHV8 is unquestionably associated with prolif-
rative disorders, including multicentric Castleman’s disease
nd Kaposi’s sarcoma. Evidence of HHV8 was found in a
arge percentage of plexiform lesions of one cohort of PH
atients, suggesting for the first time that this virus was a
ontributing factor (53). However, a number of other
nvestigators have attempted without success to find evi-
ence of latent HHV8 infection in lung tissue sections from
atients with idiopathic PAH, with immunohistochemistry
nd PCR methodology (54–57).
epatitis C virus. Finally, PH represents one of the
xtrahepatic complications of hepatitis C virus (HCV)
nfection, with a prevalence of 1% to 5% (58). In the
ajority of patients, portal hypertension precedes PH
58,59). The pathogenesis is poorly understood, but the
istologic hallmarks are similar to IPAH. Whether these
esions are secondary to increased inflammatory cytokine
roduction, direct viral replication, or presence of viral
roducts in the lung remains to be determined. In contrast,
n observational study of 823 HIV-infected patients with
nd without HCV concluded that although age, baseline
D4 cell count, and duration of highly active antiretrovi-
al therapy were significantly associated with survival, HCV
nfection was not (60). An associated immune dysregulation
ight trigger uncontrolled intrapulmonary angiogenesis, as
n HIV-mediated PH. rIn summary, very little is known about the natural history of
ny form of virus-related PH or the molecular mechanisms
hat account for the pathogenesis. Cell biological studies with
ecombinant viral proteins or with cloned virions might shed
ome light as to potential molecular mechanisms whereby viral
roteins induce angioproliferation.
AH-SSc as a Prototypic Inflammatory Disease
ascular changes in SSc and evidence for autoimmunity
s a central component of remodeling. Vascular changes
ccur at an early state in SSc and include apoptosis (61), EC
ctivation with expression of cell adhesion molecules, in-
ammatory cell recruitment, procoagulant state (62), and
ntimal proliferation and adventitial fibrosis leading to vessel
bliteration. Endothelial cell injury is reflected by increased
evels of soluble vascular cell adhesion molecule-1 (63),
isturbances in angiogenesis as reflected by increased levels
f circulating VEGF (64), and presence of angiostatic
actors (64). Dysregulated angiogenesis in PAH-SSc,
hether driven by the inflammatory process or other mech-
nisms, seems to be a predominant feature of the disease and
hould be a focus of future studies.
utoantibodies in scleroderma-related PAH. A role for
n autoimmune process has been proposed in the patho-
enesis of PAH-SSc. Antifibrillarin antibodies (anti–U3-
NP) are frequently found in PAH-SSc patients (65), and
he poorly characterized anti-endothelial cell antibodies
AECAs) correlate with digital infarcts (66). Antibodies to
brin-bound tissue plasminogen activator in patients with
imited cutaneous SSc (67) and in IPAH patients with
LA-DQ7 antigen (68) and antitopoisomerase II- anti-
odies, particularly in association with HLA-B35 antigen
69), are found in PAH-SSc. Nicolls et al. (5) suggested that
ECAs—which can activate ECs, induce the expression of
dhesion molecules, and trigger apoptosis—play a role in
AH pathogenesis. In vitro experiments using autoantibodies
rom patients with connective tissue diseases (anti–U1-RNP
nd –dsDNA) can upregulate adhesion molecules (e.g., endo-
helial leukocyte adhesion molecule-1) and histocompatibility
omplex class II molecules on human PA ECs (70), suggesting
hat an inflammatory process could lead to proliferative and
nflammatory pulmonary vasculopathy.
Fibroblasts are essential components of remodeling of the
ulmonary vascular wall in PAH and can be found in the
emodeled neointimal layer in both PAH-SSc and IPAH.
he detection of antifibroblast antibodies in the serum of
AH-SSc and IPAH patients (71,72) has significant patho-
enic importance, because these antibodies can activate
broblasts and induce collagen synthesis, thus potentially
ontributing directly to the remodeling process. Antibodies
rom sera of patients with SSc induce a proadhesive and
roinflammatory response in normal fibroblasts (72). Im-
unoglobulin G antifibroblast antibodies are present in sera
f patients with IPAH and PAH-SSc and have distinct
eactivity profiles in these 2 conditions (71). With
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June 30, 2009:S10–9 Pulmonary Vascular Remodeling-dimensional immunoblotting technique, several antigens
ecognized by serum immunoglobulin G from IPAH and
AH-SSc patients were identified, including proteins in-
olved in regulation of cytoskeletal function, cell contrac-
ion, cell and oxidative stress, cell energy metabolism, and
ifferent key cellular pathways (73). Although the specific
embrane antigens targeted by these autoantibodies remain
o be determined, it is likely that they react to membrane
omponents, because they typically bind to unpermeabilized
broblasts, and might mediate the release of cytokines and
rowth factors which in turn might contribute to the
athogenesis of vascular remodeling in PAH (71).
Taken together, particularly in light of the positive
esponse to immunosuppressive therapy for one-third of
atients with PAH associated with systemic lupus erythem-
tosus and mixed connective tissue disease (74), these
tudies suggest that inflammation and autoimmunity could
lay a major role in the pathogenesis of PAH. Thus, a
earch for specific biomarkers of inflammation could be a
ocus of future studies in IPAH, PAH-SSc, and other
utoimmune conditions associated with PAH.
nflammatory genes in SSc and scleroderma-related
AH. An increasing number of candidate genes have been
eported to be associated with SSc in different populations:
variant in the promoter of MCP-1 (75); 2 variants in
D19 (499GT, and a GT repeat polymorphism in the
=-UTR region) (76); a promoter and coding polymorphism
n TNF- (TNF- 238AG, TNF- 489AG) (77); a
ariant in the promoter of the IL-1 gene (IL1- 889T)
78); and a 3-single nucleotide polymorphism haplotype in
L-10 (79). Thus, compelling data support a genetic basis
or SSc. Despite these recent advances in genetics, little is
nown about genetic involvement in PAH-SSc. BMPR2
utations have not been identified in 2 small cohorts of
AH-SSc patients (80,81).
Recently, an association between an endoglin gene
ENG) polymorphism and PAH-SSc was identified (82).
ndoglin, a homodimeric membrane glycoprotein primarily
resent on human vascular endothelium, is part of the
GF- receptor complex. The functional significance of
he ENG polymorphism in SSc patients remains to be
etermined.
Aside from the few examples cited in the preceding text,
he genes relevant to the pathogenesis and generally poor
utcome associated with PAH-SSc have not been identi-
ed. Their definition will require robust, well-characterized
atient populations to provide adequate power for analysis.
nflammation in PH Associated With
hronic Obstructive Pulmonary Disease
ulmonary vascular remodeling is a common finding in
hronic obstructive pulmonary disease (COPD) and in
eavy smokers with normal lung function (83). Inflamma-
ory cells might contribute to the alterations of pulmonary
essels. Indeed, the extent of pulmonary vascular remodel- rng correlates with the severity of the inflammatory cell
nfiltrate in small airways (84). Furthermore, patients with
OPD have an increased number of inflammatory cells
nfiltrating the adventitia of muscular PAs, as compared
ith nonsmokers (85). This inflammatory infiltrate is
argely constituted by activated T lymphocytes with a
redominance of the CD8 T cell subset (85) without
hange in neutrophils, macrophages, and B-lymphocytes.
EGF. Patients with mild-to-moderate COPD show in-
reased expression of VEGF in PAs compared with control
onsmokers (86). The VEGF expression correlates with
rterial wall thickness, suggesting a potential role of VEGF
n the pathogenesis of pulmonary vascular remodeling in
OPD. In patients with advanced COPD and severe
mphysema, the expression of VEGF in PAs is lower than
n patients with mild-to-moderate disease and does not
iffer from control nonsmokers (86), suggesting downregu-
ation of VEGF in patients with emphysema that might
ead to EC apoptosis.
GF-. In COPD, TGF- has been implicated in con-
ective tissue deposition (87) and airway macrophage re-
ruitment (88). In patients with very severe COPD, the
xpression of type II receptor (TGF- RII) but not TGF-
s increased in the tunica media and intima of PAs (89),
long with a normal cell proliferation rate in both layers of
he vessel wall, suggesting that TGF- might exert a
rotective role (restraining cell proliferation) and that
rowth factors other than TGF- might be involved in
ulmonary vascular remodeling (89).
argeting Signaling Pathways:
he Role of Antineoplastic Drugs
n the Control of Vascular Remodeling in PAH
he concept of “targeted” therapy holds popular appeal for
dvancing cancer treatment. Imatinib, an inhibitor of Bcr-
bl kinase, has dramatically changed prognosis for patients
ith chronic myeloid leukemia (90). Although imatinib is
he archetype for targeted cancer therapeutics, it does not
xclusively inhibit Bcr-Abl but also inhibits PDGFR (91).
chermuly et al. (15) tested the effects of imatinib in rodent
odels, on the basis of evidence that PDGF signaling is an
mportant process in the pathophysiology of PAH (92). The
ffects of MCT on RV systolic pressure, cardiac index, RV
ypertrophy, and overall survival were reversed in dose-
ependent fashion with administration of imatinib, along
ith downregulation of phosphorylated PDGFR and
xtracellular signal-related kinase in lung tissue homoge-
ates. Clinical validation of imatinib as PAH therapy was
rst suggested in case reports (93–95). These led to a Phase
I trial to evaluate the safety, tolerability, and efficacy of
matinib in patients with PAH that, at the time of the PH
orld Congress, was open to accrual at multiple centers in
he U.S. and Europe.
isrupting PDGF and VEGF signaling. Although theole for specific disruption of PDGFR signaling in cancer
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Pulmonary Vascular Remodeling June 30, 2009:S10–9herapeutic regimens is still under investigation, the efficacy
f 2 U.S. Food and Drug Administration-approved agents,
unitinib and sorafenib, is attributed in part to their dual
nhibition of VEGF and PDGF signaling pathways.
hereas PDGF is a validated specific target in PH, the
ationale for testing antiproliferative drugs in advanced
uman PAH is also based on the presence of dysregulated
Figure 1 Mechanisms of Inflammation-Mediated Remodeling
This schematic features inflammatory mediators, cells, and mechanisms involved
cytokines and chemokines in remodeled vessels (e.g., plexiform lesions) or in the
mediate the influx of inflammatory cells (e.g., monocytes, T and B lymphocytes). C
motor and growth mediators, activation of transcriptional factors (e.g., nuclear fac
The net effect is a shift of balance in favor of cell proliferation and decreased apo
therapeutic target sites include inhibition of growth factors with tyrosine kinase inh
polypeptide (a competitive peptide that inhibits the docking of NFAT to calcineurin)
CCL2  chemokine (C-C motif) ligand 2; CCL5  chemokine (C-C motif) ligand 5 o
CX3CL1  chemokine (C-X3-C motif) ligand 1 (fractalkine); CX3CR1  chemokine
FGF  fibroblast growth factor; 5-HT  serotonin; HIV-1  human immunodeficien
nary arterial hypertension; PDGF  platelet-derived growth factor; PGI2  prostacyroliferation of microvascular ECs and SMCs, monoclo-
al EC expansion (96), increased expression of secreted
rowth factors such as VEGF and basic fibroblast growth
actor (97), and the fact that this condition—with its
oor prognosis—is reminiscent of advanced solid tumors
98). Also at the time of the PH World Congress, a Phase
clinical trial to determine the safety and tolerability of
onary vascular remodeling as well as potential therapeutic targets. Release of
tion, from activated endothelial cells (ECs) and smooth muscle cells (SMCs),
dysfunction (particularly involving EC and SMC) contributes to release of vaso-
ctivated T lymphocytes [NFAT]), influx of calcium, and mitochondrial dysfunction.
, leading to remodeling and narrowing of the pulmonary vascular lumen. Potential
, calcineurin with cyclosporine, and prevention of NFAT activation with VIVIT
ific mechanisms are further detailed in the text. bcl2  B-cell lymphoma 2;
ES (Regulated upon Activation, Normal T cell expressed and secreted);
motif) receptor 1; DC  dendritic cells; ET1  endothelin 1; FB  fibroblasts;
s 1; IgG  immunoglobulin G; MO  monocyte; NO  nitric oxide; PAH  pulmo-
OK  Rho kinase; VEGF  vascular endothelial growth factor.in pulm
circula
ellular
tor of a
ptosis
ibitors
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June 30, 2009:S10–9 Pulmonary Vascular Remodelingorafenib in PAH patients with stable clinical and hemo-
ynamic status on prostacyclin-based therapy was open and
ow has since been completed at the University of Chicago.
he results of these trials should help advance development
f this therapeutic strategy in PAH.
onclusions
t has become clear that inflammatory processes involving
ellular effectors, chemokines, cytokines, and growth factors
lay a preponderant role in the vascular remodeling character-
stic of PAH (Fig. 1). Recognition of these specific pathways
hould allow development of additional targeted therapy in this
isease, with the hope of altering a prognosis that has been all
oo dismal in spite of significant recent progress.
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